|
T2399 |
Bortezomib
|
Radiciol,NSC 681239,MG 341,DPBA,Brotezamide,LDP 341 |
Apoptosis
,
NF-κB
,
Proteasome
,
Autophagy
|
|
Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis. |
|
T10061 |
(1S,2S)-Bortezomib
|
Bortezomib |
Proteasome
|
|
(1S,2S)-Bortezomib (Bortezomib) is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome. |
|
T7854 |
Bortezomib-pinanediol
|
|
Proteasome
|
|
Bortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib. |
|
T3971 |
CASIN
|
Pirl1-related Compound 2 |
CDK
,
STAT
,
Ras
|
|
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM). |
|
T24130 |
HCI-2184
|
HCI2184,HCI 2184 |
|
|
HCI-2184 is an inhibitor of AXL kinase and Nek2 that acts by successfully mitigating drug resistance in bortezomib-resistant multiple myeloma. |
|
T69983 |
Ixazomib citrate EtOH
|
|
|
|
Ixazomib citrate, also known as MLN9708, is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708, after hydrol... |
|
T37581 |
SCIO 469 hydrochloride
|
|
|
|
Selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38α in vitro). Displays approximately 10-fold selectivity for p38α over p38β and 2000-fold selectivity for p38α over 20 other kinases. Reduces p38α phosphorylati... |
|
T37068 |
NR-160
|
|
|
|
NR-160 is an inhibitor of histone deacetylase 6 (HDAC6; IC50= 0.03 μM).1It is selective for HDAC6 over HDAC1, -2, -3, -4, and -8 (IC50s = 5.18, 2.26, 8.48, 55.4, and 14.7 μM, respectively). NR-160 is cytotoxic against a ... |
|
T69288 |
CEP-7055
|
|
|
|
CEP-18770 is an orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the ... |
|
T68306 |
INCB16562
|
|
|
|
INCB16562 is a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3. Treatment of myeloma cells with INCB16562 potently inhibited interleukin-6 (IL-6)-induced p... |
